Search Bar & Filters
Found 101 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating whether calderasib combined with subcutaneous pembrolizumab can better treat non-small cell lung cancer NSCLC with the KRAS G12C mutation. The study compares this combination to pembrolizumab with chemotherapy to see if it helps patients live longer without their cancer growing or spreading. This is a phase 3 clinical trial assessing treatment effectiveness and safety in participants with advanced or metastatic nonsquamous NSCLC. Participants will be randomly assigned to one of two groups. One group receives pembrolizumab plus berahyaluronidase alfa as a subcutaneous injection every 6 weeks for up to 18 cycles about 2 years, along with calderasib tablets until treatment discontinuation. The other group receives pembrolizumab plus berahyaluronidase alfa with chemotherapy drugs pemetrexed and either carboplatin or cisplatin given intravenously on specified days in the first cycles, also until discontinuation criteria are met. During the study, participants will have regular assessments including tumor scans and health questionnaires to monitor progression free survival, overall survival, response rates, and quality of life. Adverse events and treatment tolerability will also be tracked up to approximately 81 months. The study aims to provide detailed information on the impact of these treatments on cancer progression and patient well-being over time.
Actively Recruiting
Researchers are investigating new treatments for metastatic castration-resistant prostate cancer mCRPC. This study evaluates the medicine ifinatamab deruxtecan I-DXd or MK-2400 compared to chemotherapy to see if it helps people live longer overall and without cancer progression. The trial is sponsored by Merck Sharp & Dohme LLC and focuses on men with advanced prostate cancer who have tried other therapies. Participants are randomly assigned to one of two groups. One group receives I-DXd at 12 mg per kg every three weeks through intravenous infusion, along with premedication to prevent nausea and vomiting. The other group receives docetaxel chemotherapy at 75 mgm every three weeks plus daily oral prednisone. Treatments continue until the cancer worsens, side effects are unacceptable, or treatment stops for other reasons. During the study, participants will have regular assessments to monitor overall survival and how long they live without cancer progression, up to about 36 months. Researchers will also track additional outcomes like time to subsequent therapies, response rates, pain progression, and side effects. Safety and treatment tolerability will be closely monitored throughout the trial, which may last up to six years for some participants.
Actively Recruiting
Researchers are evaluating new treatment options for metastatic cervical cancer, a condition where cancer has spread from the cervix to other parts of the body. This study focuses on the safety and effectiveness of combining sacituzumab tirumotecan sac-TMT, pembrolizumab, and bevacizumab, compared to standard treatments. The research aims to understand how well these medicines work together and whether they help people live longer or delay cancer progression. The study has two parts. In Part 1, eligible participants receive sac-TMT with pembrolizumab and bevacizumab to assess safety. In Part 2, all participants first undergo standard induction treatment with pembrolizumab, paclitaxel, and cisplatin or carboplatin, with optional bevacizumab. Those whose cancer does not worsen are randomized to receive either pembrolizumab alone or sac-TMT plus pembrolizumab, with optional bevacizumab for maintenance treatment. Treatments are given by intravenous infusion at specified doses and schedules over several months. Participants will be closely monitored throughout the study with regular visits to assess safety, cancer progression, and quality of life. Researchers will track adverse events, treatment tolerability, progression-free survival, and overall survival. Quality of life questionnaires and physical functioning assessments are included to understand the impact of treatment. The study duration may extend up to approximately 69 months for safety follow-up, with various outcome measures evaluated at set intervals.
Actively Recruiting
Researchers are evaluating new treatment approaches for advanced ovarian cancer in people whose tumors are non-HRD positive. This study aims to find out if adding sacituzumab tirumotecan sac-TMT, a targeted therapy, as maintenance treatmentwith or without bevacizumabhelps patients live longer without their cancer worsening compared to standard care. This is a phase 3 randomized study involving participants who have completed surgery and first-line platinum-based chemotherapy. Participants receive sac-TMT intravenously on days 1, 15, and 29 of every 6-week cycle until their disease worsens or they experience prohibitive side effects. Some may also receive bevacizumab intravenously on days 1 and 22 every 6 weeks for up to 22 cycles, depending on the investigators choice. The comparison group receives either bevacizumab alone on the same schedule or is observed closely without maintenance treatment. During the study, participants will have regular evaluations to monitor their cancer status and quality of life. Researchers will measure progression-free survival for up to about 49 months and assess overall survival, adverse events, treatment discontinuation, and changes in quality of life scores for up to 78 months. Participants health will be followed long-term to understand treatment effects and safety over time.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of the drug rilvegostomig compared with pembrolizumab as a first-line treatment for patients with metastatic non-small cell lung cancer mNSCLC whose tumors have high levels of PD-L1. This Phase III, randomized, double-blind, global study focuses on patients with mNSCLC who meet specific genetic and health criteria to understand how these treatments perform in this group. Participants receive either rilvegostomig or pembrolizumab, both given intravenously on the first day of each 21-day treatment cycle. The study has two groups one receiving rilvegostomig and the other pembrolizumab, with treatments continuing as part of their first-line cancer care. The trial monitors these treatments over several years to assess long-term outcomes. During the study, participants will have regular assessments including scans to measure tumor response, evaluations of physical function, quality of life questionnaires, and tests to monitor drug levels and immune responses. The main outcomes tracked are overall survival and progression-free survival over approximately five years. Safety and patient-reported symptoms are also closely monitored throughout the study period.
Actively Recruiting
Researchers are evaluating the long-term safety and effects of vedolizumab given as a subcutaneous injection in children and teenagers aged 2 to 17 years who have moderate to severe active ulcerative colitis or Crohns disease. The study aims to understand any medical problems related to the treatment, the time until hospital visits due to bowel inflammation are needed, and the impact on quality of life. This is a phase 3b extension study involving participants from a previous trial who responded well or did not respond to vedolizumab treatment. Participants who responded well in the previous study will continue to receive vedolizumab subcutaneously either via a prefilled syringe with an autoinjector pen or with a needle safety device. Dosage depends on weight, with injections given every two or four weeks for up to 120 weeks or until the treatment becomes commercially available or the study ends. Those who did not respond well or recently used corticosteroids will not receive the drug but will be followed for approximately two years as an observational group. Throughout the study, participants will visit their clinic multiple times for safety monitoring and assessments. Researchers will track adverse events and serious side effects up to 18 weeks after the last dose, as well as other safety events in the observational group. They will also measure the time to major inflammatory bowel disease events and changes in quality of life using questionnaires. The total participation time can be up to two years from the first dose.
Actively Recruiting
Researchers are evaluating whether the drugs retatrutide and tirzepatide can prevent major adverse liver outcomes MALO in adults with metabolic dysfunction-associated steatotic liver disease MASLD, a condition that puts them at higher risk for severe liver problems. This Phase 3 trial is designed as a randomized, controlled study involving about 4,500 adults with MASLD identified through non-invasive tests indicating increased risk for liver complications. Participants will be randomly assigned to receive either retatrutide, tirzepatide, or a placebo, all given by subcutaneous injection. The study will last approximately 224 weeks, with up to 25 to 30 clinic visits to monitor health, conduct procedures, and assess liver function and disease progression. After completing the main study, eligible participants may join an optional 2-year extension where all receive either retatrutide or tirzepatide, regardless of initial assignment. Throughout the trial, participants will undergo assessments including liver fat content measurements, liver stiffness tests, liver fibrosis scores, and blood tests for liver enzymes and body weight changes. The primary outcome is the time until the first major adverse liver event occurs. Safety and disease progression will be closely monitored during and after treatment through regular clinic visits and evaluations.
Actively Recruiting
This research focuses on patients who developed secondary malignancies of T-cell origin after receiving tisagenlecleucel treatment. It aims to understand if tisagenlecleucel plays a role in the development of these secondary cancers. The study includes individuals treated either in clinical trials or in commercial settings who have confirmed secondary T-cell malignancies. Participants are grouped into two cohorts one from clinical trial settings who discontinued prior studies or long-term follow-up, and another from post-marketing or commercial use, including those treated under special access programs. No new treatments are given, as this is an observational study collecting existing tissue and blood samples for analysis over approximately 15 years. During the study, researchers will analyze available tumor tissue and blood DNA samples to test for specific markers related to tisagenlecleucel. They will measure factors such as vector copy number and test for replication-competent lentivirus. Consent is required, and samples come from routine care. The study will track these measures at screening and continue to enroll eligible participants over many years.
Actively Recruiting
Researchers are studying the effects of fenfluramine hydrochloride compared to a placebo in people with Rett syndrome, a genetic neurological disorder. This Phase 3 clinical trial aims to assess how well fenfluramine hydrochloride works and its safety in improving symptoms of Rett syndrome, with outcomes measured by changes in behavior and clinical impressions over 14 weeks. Participants receive fenfluramine hydrochloride or placebo orally during a 14-week double-blind period, including dose adjustment and maintenance. After this, all participants enter a 2-week transition period, then a 52-week open-label phase where they receive fenfluramine hydrochloride. Those who stop treatment without continued access undergo an 8-day medication taper and a 26-week follow-up. Throughout the trial, participants undergo assessments including questionnaires on behavior, sleep, communication, and caregiver impressions, as well as heart monitoring via ECG and echocardiograms to watch for side effects. Safety and adverse events are tracked up to nearly four years. The study involves regular visits during treatment and follow-up periods, aiming to measure changes in Rett syndrome symptoms and overall clinical status.
Actively Recruiting
Researchers are evaluating AZD8205, a new antibody drug conjugate, as a possible treatment for advanced or metastatic solid tumors including breast cancer, biliary tract carcinoma, ovarian cancer, endometrial cancer, and squamous non-small cell lung cancer. This Phase IIIa multi-center, open-label study aims to assess AZD8205 alone or combined with other anti-cancer agents to determine safety, tolerability, dosing, and anti-tumor activity. The study includes multiple sub-studies focusing on different drug combinations and tumor types. Participants may receive AZD8205 as monotherapy or in combination with rilvegostomig, saruparib, and AZD9574. The study has dose escalation phases to identify the recommended phase 2 dose and expansion phases to evaluate anti-tumor effects in selected solid tumors. Some combinations may involve triplet therapies depending on emerging safety data. Treatments will be given according to protocol schedules within each sub-study. Throughout the study, participants will undergo regular monitoring for adverse events, lab tests, ECGs, vital signs, and pharmacokinetic assessments for up to two years. Researchers will measure outcomes such as response rates, duration of response, progression-free survival, overall survival, and immunogenicity. Safety evaluations continue from informed consent to 30 days after the last dose. The study is randomized and open-label, with ongoing assessments during treatment and follow-up periods.
1-10 of 101
1